Vimarsana
Biggest News Aggregation in the World

Page 4 - Jonathan Silverberg News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Jonathan Silverberg. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Jonathan Silverberg Today - Breaking & Trending Today

Clinical Challenges: Is Recalcitrant Atopic Dermatitis Really Comorbid Disease? - Vimarsana News

Clinical Challenges: Is Recalcitrant Atopic Dermatitis Really Comorbid Disease?

Dupilumab failure signals the need for extended patch testing to identify a missed diagnosis

Clinical Challenges: JAK Inhibitors for Atopic Dermatitis - Vimarsana News

Clinical Challenges: JAK Inhibitors for Atopic Dermatitis

Strong efficacy data for new class of agents in AD, but some apprehension over safety warnings

ASLAN Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update - Vimarsana News

ASLAN Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update

27.10.2023 - Positive topline data reported in July from TREK-AD, a Phase 2b study of eblasakimab in moderate-to-severe atopic dermatitis, met the primary endpoint across three dosing arms; the study established eblasakimab’s potential to deliver a monthly ...

2023-10-24 | NDAQ:ASLN | Press Release | Aslan Pharmaceuticals Ltd - Vimarsana News

2023-10-24 | NDAQ:ASLN | Press Release | Aslan Pharmaceuticals Ltd

(2023-10-24 | NDAQ:ASLN) ASLAN Pharmaceuticals to Co-Host KOL Panel Discussion Today on Changes in the Clinical Trial and Treatment Landscape for Atopic Dermatitis

Recombinant IL-2 Shows Potential in Atopic Dermatitis - Vimarsana News

Recombinant IL-2 Shows Potential in Atopic Dermatitis

"This is the first study to demonstrate the therapeutic potential of rezpegaldesleukin," said Jonathan Silverberg, MD, PhD, MPH, who presented results of a phase 1b study.